Thrombogenics

LEUVEN, Belgium and LUND, Sweden, December 16, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.

LEUVEN, Belgium, October 20, 2011 - Leading retinal specialist also invited to present ocriplasmin responder analysis forthe treatment of macular holes at Best of the Posterior Segment Specialty Meetings ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that three leading retinal specialists will present the responder analysis on ocriplasmin, a potentially novel treatment for retinal disorders, at the 2011 AAO Annual Meeting in Orlando, USA (21-25 October 2011).